Squamous cell carcinoma - Karsinoma Sela Squamous
☆ Tamin'ny valin'ny Stiftung Warentest 2022 avy any Alemaina, ny fahafaham-pon'ny mpanjifa amin'ny ModelDerm dia ambany kely noho ny fifampidinihana telemedicine karama.
Squamous cell carcinoma well differentiated ― Misy keratosis actinika mifanila aminy.
References
Squamous cell carcinoma (SCC) no homamiadan'ny hoditra faharoa fahita indrindra any Etazonia, taorian'ny basal cell carcinoma. Matetika izy io dia manomboka amin'ny ratra mialohan'ny homamiadana antsoina hoe actinic keratosis , ary mety hiparitaka any amin'ny faritra hafa amin'ny vatana. Ny tena antony dia ny fiposahan'ny taratra ultraviolet (UV) avy amin'ny masoandro, izay miangona rehefa mandeha ny fotoana. Ny fitsaboana matetika dia ny fanesorana fandidiana, indrindra ho an'ny SCC eo amin'ny loha sy ny tendany. Ny fitsaboana amin'ny taratra dia safidy ho an'ny marary efa lehibe na tsy afaka fandidiana. Ny immunosuppression dia mampitombo ny mety ho voan'ny SCC. Na dia tsy fahita firy aza, dia mety hiparitaka ny SCC, indrindra amin'ireo marary manana rafi-kery fanefitra malemy. Ny fanaraha-maso tsy tapaka sy ny fiarovana amin'ny masoandro dia zava-dehibe ho an'ireo manana SCC.
Squamous cell carcinoma of the skin or cutaneous squamous cell carcinoma is the second most common form of skin cancer in the United States, behind basal cell carcinoma. Squamous cell carcinoma has precursor lesions called actinic keratosis, exhibits tumor progression and has the potential to metastasize in the body. Ultraviolet (UV) solar radiation is the primary risk factor in the development of cutaneous squamous cell carcinoma and the cumulative exposure received over a lifetime plays a major part in the development of this cancer. Surgical excision is the primary treatment modality for cutaneous squamous cell carcinoma, with Mohs micrographic surgery being the preferred excisional technique for squamous cell carcinoma of the head and neck, and in other areas of high risk or squamous cell carcinoma with high-risk characteristics. Radiation therapy is reserved for squamous cell carcinoma in older patients or those who will not tolerate surgery, or when it has not been possible to obtain clear margins surgically. Adjuvant radiotherapy is commonly after surgical treatment in very high tumors. Immunosuppression significantly increases the risk of squamous cell carcinoma over the course of an individual’s life. Metastasis is uncommon for squamous cell carcinomas arising in areas of chronic sun exposure, but it can take place, and the risk is increased in immunosuppressed patients. Patients with cutaneous squamous cell carcinoma should be examined regularly and remember to use measures to protect from UV damage.
Squamous cell carcinoma of the skin or cutaneous squamous cell carcinoma is the second most common form of skin cancer in the United States, behind basal cell carcinoma. Squamous cell carcinoma has precursor lesions called actinic keratosis, exhibits tumor progression and has the potential to metastasize in the body. Ultraviolet (UV) solar radiation is the primary risk factor in the development of cutaneous squamous cell carcinoma and the cumulative exposure received over a lifetime plays a major part in the development of this cancer. Surgical excision is the primary treatment modality for cutaneous squamous cell carcinoma, with Mohs micrographic surgery being the preferred excisional technique for squamous cell carcinoma of the head and neck, and in other areas of high risk or squamous cell carcinoma with high-risk characteristics. Radiation therapy is reserved for squamous cell carcinoma in older patients or those who will not tolerate surgery, or when it has not been possible to obtain clear margins surgically. Adjuvant radiotherapy is commonly after surgical treatment in very high tumors. Immunosuppression significantly increases the risk of squamous cell carcinoma over the course of an individual’s life. Metastasis is uncommon for squamous cell carcinomas arising in areas of chronic sun exposure, but it can take place, and the risk is increased in immunosuppressed patients. Patients with cutaneous squamous cell carcinoma should be examined regularly and remember to use measures to protect from UV damage.
Cutaneous squamous cell carcinoma (CSCC) no homamiadana faharoa fahita indrindra amin'ny olona, ary miakatra ny isany. Na dia mampiseho fitondran-tena tsara aza ny CSCC, dia mety hiparitaka eo an-toerana sy any amin'ny faritra hafa amin'ny vatana. Ny mpahay siansa dia nahita lalana manokana tafiditra amin'ny fampandrosoana ny CSCC, mitondra amin'ny fitsaboana vaovao. Ny hamaroan'ny fiovan'ny toetr'andro sy ny fitomboan'ny risika amin'ny marary voan'ny immunosuppresse dia nahatonga ny fivoaran'ny immunotherapy. Ity famerenana ity dia mijery ny fototarazon'ny CSCC sy ny fitsaboana farany mikendry ny molekiola manokana sy ny hery fiarovana.
Cutaneous squamous cell carcinoma (CSCC) is the second most frequent cancer in humans and its incidence continues to rise. Although CSCC usually display a benign clinical behavior, it can be both locally invasive and metastatic. The signaling pathways involved in CSCC development have given rise to targetable molecules in recent decades. In addition, the high mutational burden and increased risk of CSCC in patients under immunosuppression were part of the rationale for developing the immunotherapy for CSCC that has changed the therapeutic landscape. This review focuses on the molecular basis of CSCC and the current biology-based approaches of targeted therapies and immune checkpoint inhibitors
Cutaneous squamous cell carcinoma (CSCC) is the second most frequent cancer in humans and its incidence continues to rise. Although CSCC usually display a benign clinical behavior, it can be both locally invasive and metastatic. The signaling pathways involved in CSCC development have given rise to targetable molecules in recent decades. In addition, the high mutational burden and increased risk of CSCC in patients under immunosuppression were part of the rationale for developing the immunotherapy for CSCC that has changed the therapeutic landscape. This review focuses on the molecular basis of CSCC and the current biology-based approaches of targeted therapies and immune checkpoint inhibitors
○ Diagnose sy Fitsaboana
#Dermoscopy
#Skin biopsy